BIOLOGICAL · Unmapped registry intervention
Anti-PD-1 plus DC-CIK
Find medicine records ·
Find other trials using this name
Clinical trial
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
NCT03360630
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
BIOLOGICAL · Unmapped registry intervention
Anti-PD-1 alone
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedAnti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Lung Cancerverified · MONDO: lung cancer
Neoplasmsunresolved
Interventions
Anti-PD-1 plus DC-CIKBIOLOGICAL
Anti-PD-1 aloneBIOLOGICAL
Sponsors & collaborators
Capital Medical Universitylead sponsor
Duke Universitycollaborator
Geneplus-Beijing Co. Ltd.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03360630 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.